Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 7/20 | 0.44 |
| ▸ | KDR | P35968 | 8/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | CSK | P41240 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913998 | 0.91 | EPHB4 (0.42) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL5262710 | 0.91 | EPHB4 (0.42) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL5914384 | 0.90 | CFD (0.41) | EPHB4KDRMAPK14DYRK1B | |
| SCHEMBL5317833 | 0.86 | KDR (0.40) | EPHB4KDRFGFR1MAPK14 | |
| SCHEMBL5314939 | 0.86 | KDR (0.40) | EPHB4KDRFGFR1MAPK14 | |
| SCHEMBL5265551 | 0.85 | EPHB4 (0.42) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL5266761 | 0.84 | EPHB4 (0.39) | EPHB4KDRFGFR1MAPK14 | |
| SCHEMBL5914253 | 0.84 | EPHB4 (0.39) | EPHB4KDRFGFR1MAPK14 | |
| SCHEMBL5312681 | 0.83 | EPHB4 (0.37) | EPHB4KDRFGFR1MAPK14CSK | |
| SCHEMBL5310133 | 0.83 | EPHB4 (0.38) | EPHB4KDRFGFR1MAPK14CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | EPHB4 1411/4885KDR 210/4885FGFR1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.